August 24, 2016 1:57 AM ET

Pharmaceuticals

Company Overview of Jounce Therapeutics, Inc.

Company Overview

Jounce Therapeutics, Inc. engages in the discovery and development of a pipeline of cancer immunotherapy treatments for a range of cancers. Its immunotherapies are designed to harness the patient's immune system to seek out and attack cancerous cells and tumors. Jounce Therapeutics, Inc. has a strategic collaboration with Celgene Corp. The company was incorporated in 2012 and is based in Cambridge, Massachusetts.

1030 Massachusetts Avenue

Cambridge, MA 02138

United States

Founded in 2012

Phone:

617-585-2000

Fax:

617-859-2891

Key Executives for Jounce Therapeutics, Inc.

Chief Executive Officer and President
Age: 57
Compensation as of Fiscal Year 2016.

Jounce Therapeutics, Inc. Key Developments

Celgene Corp Forms Collaboration with Jounce Therapeutics to Develop Cancer Immunotherapies

Celgene Corp. (CELG) and Jounce Therapeutics have formed a strategic collaboration to develop and commercialize immuno-oncology treatments for cancer patients. The collaboration includes options on Jounce's lead product candidate JTX-2011 and up to four early-stage programs emerging from the Jounce Translational Science Platform as well as an option to equally share a checkpoint immuno-oncology program. Under the terms of the collaboration, Jounce will receive a $225 million upfront payment and a $36 million equity investment from Celgene. Jounce also stands to receive up to $2.3 billion in milestone payments from all programs reaching commercialization.

Jounce Therapeutics, Inc. Presents at Cantor Fitzgerald 2nd Annual Healthcare Conference, Jul-13-2016 04:00 PM

Jounce Therapeutics, Inc. Presents at Cantor Fitzgerald 2nd Annual Healthcare Conference, Jul-13-2016 04:00 PM. Venue: Le Parker Meridien, New York, New York, United States.

Jounce Therapeutics, Inc. Appoints Barbara G. Duncan to its Board of Directors

Jounce Therapeutics, Inc. announced the appointment of Barbara G. Duncan to the company's board of directors. Ms. Duncan brings to the company almost 30 years of financial leadership experience, with over 15 of those years in management roles within the pharmaceutical industry. Ms. Duncan has spent the last seven years as chief financial officer and treasurer at Intercept Pharmaceuticals, Inc. Previously, Ms. Duncan held various senior leadership roles of increasing responsibility at DOV Pharmaceutical, Inc., including as chief executive officer.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
July 19, 2016
--
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Jounce Therapeutics, Inc., please visit www.jouncetx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.